Alerts will be sent to your verified email
Verify Email
LUPIN
|
Lupin
|
Zydus Lifesciences
|
Mankind Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
6.43 % | 18.47 % | 20.33 % |
|
5yr Avg Net Profit Margin
|
5.06 % | 19.02 % | 17.68 % |
|
Price to Book
|
5.04 | 4.16 | 7.25 |
|
P/E
|
23.44 | 21.8 | 54.93 |
|
5yr Avg Cash Conversion Cycle
|
-84.38 Days | -84.89 Days | -13.08 Days |
|
5yr Average Interest Coverage Ratio
|
6.26 | 30.19 | 46.07 |
|
5yr Avg ROCE
|
10.02 % | 19.65 % | 25.06 % |
|
5yr Avg Operating Profit Margin
|
14.15 % | 24.4 % | 24.62 % |
|
5 yr average Debt to Equity
|
0.3 | 0.17 | 0.16 |
|
5yr CAGR Net Profit
|
21.95 % | 16.23 % | 9.49 % |
|
5yr Average Return on Assets
|
3.91 % | 12.22 % | 14.46 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
46.9 % | 74.99 % | 72.68 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.2 % | 0.11 % | -3.82 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.49 % | 0.94 % | 5.51 % |
|
Lupin
|
Zydus Lifesciences
|
Mankind Pharma
|
|---|